Insulin Degludec

證據等級: L5

預測適應症: 6 個

Insulin Degludec: A Self-Referential Prediction (Diabetes Mellitus → Type 1 Diabetes Mellitus)

One-Sentence Summary

Insulin degludec is a long-acting (ultra-long-acting) basal insulin analogue used for diabetes mellitus management. The TxGNN model's top-ranked prediction (Type 1 Diabetes Mellitus, score 99.44%) is not a genuine repurposing signal — it corresponds to the drug's own known clinical use — but the evidence pack is well supported by 58 clinical trials and 20 publications, including multiple completed Phase 3 RCTs. The remaining five ranked candidates in this pack are weaker, exploratory signals with little-to-no direct evidence.

Quick Overview

Item	Content
Original Indication	Diabetes mellitus, basal insulin therapy (exact regulatory indication text not provided in evidence pack — data gap)
Predicted New Indication	Type 1 Diabetes Mellitus (self-referential — see caveat below)
TxGNN Prediction Score	99.44%
Evidence Level	L1 (≥2 completed Phase 3 RCTs)
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold (for repurposing purposes — see rationale)

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data for insulin degludec is not available in this evidence pack (data gap). Based on established pharmacological knowledge, insulin degludec is an ultra-long-acting basal insulin analogue that forms soluble multihexamers after subcutaneous injection, which are then slowly and continuously released into circulation — giving it a flat, stable, ~24+ hour action profile. It is used as exogenous replacement therapy for patients with absolute or relative insulin deficiency.

Important caveat on Rank 1: The repurposing rationale supplied with this evidence pack explicitly states that "type 1 diabetes mellitus" is insulin degludec's original, already-approved indication — not a novel repurposing candidate. TxGNN has effectively re-discovered the drug's own known use. This is a known limitation of graph-based drug–disease link prediction models: high-confidence edges can reflect existing knowledge already embedded in the training graph rather than a genuinely new therapeutic hypothesis. The extensive clinical trial and literature evidence below therefore should be read as confirmatory evidence of established efficacy, not as support for a new indication.

The genuinely exploratory candidates in this pack (ranks 2–6, summarized further below) are mechanistically much weaker: most reflect disease comorbidity (e.g., shared anti-GAD65 autoimmunity between Type 1 diabetes and stiff person syndrome) rather than a direct pharmacological effect of insulin on the predicted disease itself.

Clinical Trial Evidence

(for predicted_indications[0] — "type 1 diabetes mellitus," which is the drug's known/original indication)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05463744	Phase 3	Completed	692	Once-weekly insulin efsitora alfa vs. insulin degludec in T1D patients on multiple daily injections
NCT03214367	Phase 3	Completed	1392	PRONTO-T1D: LY900014 vs. insulin lispro, both combined with glargine or degludec, in T1D
NCT02500706	Phase 3	Completed	1108	Faster-acting insulin aspart vs. NovoRapid, both combined with degludec, in adults with T1D
NCT01835431	Phase 3	Completed	362	IDegAsp once daily + aspart vs. detemir once/twice daily + aspart in children/adolescents with T1D
NCT04450407	Phase 2	Completed	266	LY3209590 vs. insulin degludec in T1D patients previously on multiple daily injections
NCT05767255	Phase 3	Unknown	66	Basal-bolus insulin (incl. degludec) vs. basal insulin + GLP-1 analogue for hypoglycemia risk at hospital discharge
NCT02536859	Phase 1	Completed	60	PK/PD comparison of degludec vs. glargine U300 at steady state in T1D
NCT00841087	Phase 2	Completed	65	Safety of degludec + NovoRapid vs. detemir + NovoRapid, basal-bolus regimen, in Japanese T1D patients
NCT03400501	Early Phase 1	Completed	32	School-supervised degludec vs. glargine to reduce ketosis risk in adolescents with poorly-controlled T1D
NCT00992537	Phase 1	Completed	27	PK/PD comparison of IDegAsp, degludec, and insulin aspart in T1D

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37863084	2023	RCT	Lancet	ONWARDS 6: once-weekly insulin icodec vs. once-daily degludec, basal-bolus regimen, in T1D
39270686	2024	RCT	Lancet	QWINT-5: once-weekly efsitora alfa vs. once-daily degludec in adults with T1D
36623517	2023	RCT	Lancet Diabetes Endocrinol	EXPECT: degludec vs. detemir (both + aspart) in pregnant women with T1D — non-inferiority trial
34643020	2022	RCT	Diabetes Obes Metab	HypoDeg: degludec vs. glargine U100 in T1D patients prone to nocturnal severe hypoglycemia
36610544	2023	RCT	Diabetes Res Clin Pract	INEOX: degludec 100 IU/mL vs. glargine 300 IU/mL efficacy/safety in T1D
34763071	2022	RCT	Endocr Pract	BIGLEAP: degludec vs. aspart via insulin pump in well-controlled T1D, crossover design
36516429	2023	RCT	Diabetes Technol Ther	ULTRAFLEXI-1: glargine U300 vs. degludec U100 around spontaneous exercise in T1D
36763996	2022	Systematic Review / Meta-analysis	Clin Ther	Degludec vs. other long-acting basal insulins in T1D/T2D — efficacy and tolerability
35476308	2022	Systematic Review	Int J Clin Pharm	Degludec U100 vs. glargine U300 in T1D — safety, efficacy, cost-effectiveness
29477399	2018	Systematic Review / Network Meta-analysis	Value Health	Basal insulin regimens for adults with T1D — comparative efficacy and safety

Other Predicted Indications (Exploratory, Lower Evidence)

This evidence pack contains five additional TxGNN-ranked candidates. None currently have supporting clinical trials or literature. Summarized for completeness:

Rank	Disease	Score	Evidence Level	Recommendation	Note
2	Autoimmune oophoritis	99.23%	L5	Hold	No mechanistic link identified beyond possible co-occurrence in autoimmune polyglandular syndrome; pure model artifact
3	Opsismodysplasia	99.12%	L5	Hold	Rare skeletal dysplasia (INPPL1 mutation); no known interaction with insulin signaling
4	Thiamine-responsive dysfunction syndrome (TRMA)	99.10%	L4	Research Question	TRMA includes diabetes as part of its triad; insulin would only treat the diabetic component symptomatically, not the underlying B1-transporter defect
5	Classic stiff person syndrome	99.08%	L4	Research Question	Shares anti-GAD65 autoantibody pathophysiology with T1D (co-occurs in ~30–40% of SPS patients); insulin treats comorbid diabetes only, not SPS neurological symptoms
6	Focal stiff limb syndrome	99.08%	L4	Research Question	SPS-spectrum variant; same anti-GAD65/T1D comorbidity caveat as Rank 5

None of these warrant advancement without independent mechanistic or clinical evidence.

Taiwan Market Information

Insulin degludec currently holds no marketing authorizations in Taiwan (market status: Not marketed; 0 licenses on file).

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data were available in this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked candidate (Type 1 Diabetes Mellitus) is not a novel repurposing opportunity — it is insulin degludec's existing approved use, so it offers no new business or clinical value despite its strong L1 evidence base. The remaining five candidates all carry weak evidence (L4–L5), and several (autoimmune oophoritis, opsismodysplasia) lack any credible mechanistic rationale. The two most biologically plausible exploratory leads — stiff person syndrome and focal stiff limb syndrome — represent disease comorbidity via shared anti-GAD65 autoimmunity, not a direct pharmacological effect of insulin on the neurological disorder itself, and therefore do not currently support a repurposing claim.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA label/package insert (warnings, contraindications) before any S1 safety evaluation can begin
Resolve DG002 (High): retrieve formal mechanism-of-action data from DrugBank
If pursuing the stiff person syndrome hypothesis, commission a targeted literature review of anti-GAD65 autoimmunity and insulin's potential immunomodulatory (not glycemic) role — current evidence pack contains zero supporting citations
Deprioritize autoimmune oophoritis and opsismodysplasia unless new mechanistic evidence emerges
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.